1 recruiting. .
Follow Daniel Keizman: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors Serum Gal-3 level, blood count and chemistry included liver function - Renal Cell Carcinoma (Kidney Cancer), Non Small Cell Lung Cancer | Recruiting | Daniel Keizman | 300 | 2025-12-03 | 2026-03-20 |
Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Kidney Neoplasms (1)
Blood Cell Count (1)
Israel (1)